Rinvoq Clinical Prior Authorization begins March 3
FirstCare will implement the Rinvoq (upadacitinib) clinical prior authorization criteria on March 3, 2020. All clinical edit criteria can be found here. New Rinvoq criteria will be included within the existing Cytokine and CAM Antagonists criteria guide. Rinvoq is a Janus Kinase inhibitor for treatment of adults with moderate-to-severe active rheumatoid arthritis who have not responded adequately, or are intolerant, to methotrexate. The Texas DUR Board approved the criteria at the Oct. 2019 meeting.
* Required field
ATTENTION: By clicking “Continue”, you will be leaving the FirstCare Medicare Dual SNP (HMO SNP) site pages. If you wish to remain on these pages, simply click “Cancel” or close this box.